bluebird bio researches and develops gene therapies for severe genetic diseases. Product candidates include ZYNTEGLO for transfusion-dependent ß-thalassemia, lovotibeglogene autotemcel for sickle cell disease, and SKYSONA for cerebral adrenoleukodystrophy. Clinical programs evaluate safety and efficacy of lovo-cel and beti-cel in treating SCD and ß-thalassemia patients. The company has a license agreement with Orchard Therapeutics Limited. bluebird bio was formerly Genetix Pharmaceuticals, renamed in 2010. It was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |